Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure with Reduced Ejection Fraction: Current Evidence and Future Perspectives

Publikation: Bidrag til tidsskriftReviewForskningpeer review

DOI

  1. Use of chlorprothixene and the risk of diabetes and major adverse cardiovascular events: A nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. COVID-19 clinical trials: Ethical and scientific consequences of the RECOVERY trial results

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Active chlordiazepoxide metabolites in a patient needing life support after treatment of alcohol abstinence

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Polypharmacy in schizophrenia

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  5. Acetaminophen toxicity induces mitochondrial complex I inhibition in human liver tissue

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Three decades of heart transplantation: experience and long-term outcome

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Advanced heart failure: guideline-directed medical therapy, diuretics, inotropes, and palliative care

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. Healthcare resource use of patients with transthyretin amyloid cardiomyopathy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Severity of anaemia and association with all-cause mortality in patients with medically managed left-sided endocarditis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: The sodium-glucose co-transporter-2 (SGLT2) inhibitors were developed as glucose-lowering drugs to treat type 2 diabetes (T2D). However, significant reductions in clinical outcomes have now been demonstrated in patients with heart failure with reduced ejection fraction (HFrEF), irrespective of the presence of T2D. Multiple hypotheses have been proposed for the underlying mechanisms, and the data to support these proposals are emerging.

OBJECTIVES: To review the clinical outcome data with SGLT2 inhibitors in HFrEF and the data to support the mechanisms for these clinical effects.

METHODS: Literature review was supported by a PubMed search for relevant articles up to 19 April 2022.

FINDINGS: Current data support increased diuresis and reverse cardiac remodelling as important mechanisms for the reductions in heart failure hospitalizations and mortality observed with SGLT2 inhibitors (empagliflozin or dapagliflozin) in patients with HFrEF. Alteration in intrarenal haemodynamic is likely contributing to the observed renoprotective effect of SGLT2 inhibitors.

CONCLUSIONS: Solid clinical data support the current recommendations to use empagliflozin or dapagliflozin in HFrEF. The underlying mechanisms likely include changes in cardiac and intrarenal haemodynamic. Yet, these mechanisms do not seem to solely explain the observed magnitude of clinical effect with SGLT2 inhibitors in HFrEF, and other mechanisms may contribute.

OriginalsprogEngelsk
TidsskriftBasic & clinical pharmacology & toxicology
ISSN1742-7843
DOI
StatusE-pub ahead of print - 5 maj 2022

Bibliografisk note

This article is protected by copyright. All rights reserved.

ID: 77928623